232.64USD-1.87%Mkt Cap: —P/E: —1d ago
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for h…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value30.19B $
Revenue (TTM)4.80B $
Gross Profit3.83B $
Net Income (TTM)774.71M $
Revenue/Share36.24 USD
Last Price232.64 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS02043Q1076
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA28.63
EV/Revenue6.28
P/S—
P/B22.73
EPS (TTM)-7.49
EPS (Forward)—
52W Range
218.8044% of range249.99
52W High249.99 USD
52W Low218.80 USD
Profitability
Gross Margin79.65%
Oper. Margin17.93%
EBITDA Margin21.95%
Profit Margin16.13%
ROE96.56%
ROA12.34%
Growth
Revenue Growth66.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF911.81M $
CapEx (TTM)—
FCF Margin5.65%
FCF Yield—
Net Debt-320.66M $
Net Debt/EBITDA-0.30
Balance Sheet
Debt/Equity220.62
Current Ratio3.06
Quick Ratio2.79
Book Value/Sh10.13 USD
Cash/Share24.72 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.101.03M
Float133.24M
Insiders0.18%
Institutions101.68%
Technical
SMA 50170.73 (+36.3%)
SMA 200180.79 (+28.7%)
Beta0.28
S&P 52W Chg20.80%
Avg Vol (30d)660
Avg Vol (10d)346
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—